Page 238«..1020..237238239240..250260..»

Cardio Diagnostics To Sponsor, Participate in the American Heart Association’s 2022 Metro Chicago Heart Walk – Yahoo Finance

Posted: September 16, 2022 at 2:24 am

CHICAGO, Sept. 14, 2022 /PRNewswire/ --Cardio Diagnostics, Inc. ("Cardio Diagnostics"), a pioneering precision cardiovascular medicine company, announced they will sponsor and participate in the American Heart Association's 2022 Metro Chicago Heart Walk. The event will occur at Soldier Field (410 Museum Campus Dr, Chicago, IL 60605) on September 16, 2022.

"We're thrilled to be able to support a wonderful cause that will bring attention and funding to such a critical issue."

Non-profit agencies like the American Heart Associationplay a critical role in educating the public about heart disease and its risk factors. The American Heart Association also works with partners to promote heart-healthy policies, such as tobacco control measures, and supports research to further our understanding of this complex condition.

"We're thrilled to be able to support a wonderful cause that will bring attention and funding to such a critical issue," stated Meesha Dogan, co-founder, and CEO of Cardio Diagnostics. "It takes multiple stakeholders working together to address heart disease. By collaborating and sharing resources, we can make a real difference in the fight against this leading cause of death in the United States."

Cardio Diagnostics' test, Epi+Gen CHD, is a clinical test that was recently commercialized to assess the 3-year risk for coronary heart disease, the most common type of heart disease and the primary cause of heart attacks.Epi+Gen CHD is a scientifically backed clinical test that is based on an individual's objective genetic and epigenetic DNA biomarkers. In a peer-reviewed study done in collaboration with Intermountain Healthcare (Dogan, Meeshanthini & Knight, Stacey & Dogan, Timur & Knowlton, Kirk & Philibert, Robert. (2021). External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease. Epigenomics. 13. 10.2217/epi-2021-0123), this test demonstrated a 76% and 78% sensitivity for men and women, respectively, for three-year CHD risk.

Story continues

This means that for every 100 men and 100 women deemed "at-risk" for a coronary heart disease event, the test correctly identifies 76 men and 78 women. In comparison, the average sensitivity of the Framingham Risk Score and the ASCVD Pooled Cohort Equation was found to be 44% and 32% for men and women, respectively. Epi+Gen CHD is approximately 1.7 times and 2.4 times more sensitive than the current lipid-based clinical risk estimators in men and women, respectively.

More details about the Chicago and surrounding area Heart Walk events can be found here.

About Cardio Diagnostics, Inc.:

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company's vision is to transform medical care for cardiovascular disease from reactive to proactive. With prevention and early detection as the new norm, epigenetics-based technologies driven by artificial intelligence will usher in an era of Precision Cardiovascular Medicine. The company's flagship solutions were developed in partnership with dedicated scientists and clinicians; the Cardio Diagnostics' Epi+Gen CHD test helps clinicians better assess each patient's risk profile for cardiovascular disease. For more information, see https://cardiodiagnosticsinc.com/.

No Offer or Solicitation

On May 31, 2022, Cardio Diagnostics, Inc. announced that the Company had entered into a definitive business combination agreement with Mana Capital Acquisition Corp. ("Mana"). Mana has filed a Form S-4 Registration Statement/proxy statement with the Securities and Exchange Commission in connection with the proposed Business Combination.

This press release is not a proxy statement or solicitation of a proxy, consent, or authorization concerning any securities or in respect of the proposed Business Combination. It shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Mana or Cardio, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except utilizing a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Contact:Khullani M. Abdullahi. JDpr@cardiodiagnosticsinc.com

Cision

View original content:https://www.prnewswire.com/news-releases/cardio-diagnostics-to-sponsor-participate-in-the-american-heart-associations-2022-metro-chicago-heart-walk-301624186.html

SOURCE Cardio Diagnostics, Inc.

Read the rest here:
Cardio Diagnostics To Sponsor, Participate in the American Heart Association's 2022 Metro Chicago Heart Walk - Yahoo Finance

Posted in Epigenetics | Comments Off on Cardio Diagnostics To Sponsor, Participate in the American Heart Association’s 2022 Metro Chicago Heart Walk – Yahoo Finance

Book review: Daughters and the stories they carry – Yahoo News

Posted: September 16, 2022 at 2:24 am

Sep. 9Jamie Ford's new novel is part historical fiction, part feminist fiction, part science fiction and totally captivating.

"The Many Daughters of Afong Moy" grabs the reader's attention from the beginning and holds it through generations of a mythical family that jumps to life on these pages.

It follows the tale of a real woman, Afong Moy, the first recognized Chinese woman immigrant to America. Although not much is known about her, Ford imagines a family journey through the lens of recent psychological studies that suggest trauma can be passed between generations. It's called epigenetics and Ford uses the developing research to drive the story.

Not much is really known about what happened to Afong after she was brought to America by white traders and then exhibited as a sideshow attraction to sell wares from the Far East. With her bound feet and exotic beauty, she was an early brand ambassador and influencer, although not in the glamorous way currently portrayed on social media. She was abused by her handlers and, after a brief sensation as a curiosity who made headlines across the nation, disappeared, forgotten to history.

Using the theory of shared generational trauma, however, Ford brings her back to life and fills in blanks about what could have happened to the women who followed her.

Ford's intense research into the science behind the plot lends a strong credibility to the story and sweeps the reader away into the world of Afong and her possible female progeny.

Based on real-life studies at Emory University, New York's Mount Sinai Hospital and other venerable institutions, researchers have shown that trauma of past generations could be passed along, for example, in families of Holocaust survivors and Native Americans. It's been themes in other books reviewed in these pages, such as "Red Paint," the memoir by Sasha taqweblu LaPointe.

Ford then weaves this topic with the beliefs of Buddhism and karma, which partner perfectly in driving this fascinating storyline.

Story continues

He explores all of that through Afong's story and what might have happened to her descendants: a girl who escapes the Barbary Plague in San Francisco's Chinatown at the turn of the 20th century, a brilliant British boarding school student in the 1920s, a World War II nurse, the developer of a dating app, the future poet laureate of Washington, and her daughter.

Throughout, Ford weaves the details of their lives together, not just through their tribulations but even through the music they listen to and the poetry they unintentionally pass along to one another.

Nature rarely cooperates, as Ford imagines a future 20 years away, where the rains of Seattle churn into an annual typhoon season that floods streets and destroys buildings the way hurricanes are ravaging the South. Spokane contends with a contingency of white nationalists and fire season.

After a particularly destructive storm in 2043, people in the Seattle subway show special kindness, patience, and charity to one another. "Even the Amazon workers looked happy," Ford writes. The ancillary characters are fully formed, even when most of them are causing pain.

It's easy to fall in love with Afong Moy and all her daughters. Despite the years that pass, they never seem to rise above the struggles of just being a woman. Even when they succeed, they are one step away from a man stepping in to rob them of the success they may attain, or dignity they hope to hold close.

Stories of pandemics, failures of immigration policies, misogyny, racism and the fickle tech industry all come together to create a story of the past and future clearly relevant with our present.

This is an emotional ride that keeps you flipping pages to find out what will happen to these strong, loving women working so hard to overcome the trauma that haunts and burdens them.

Because no matter what's thrown at them, they manage to maintain hope.

And this really is a book about hope.

Sometimes, it's all we have left.

Excerpt from:
Book review: Daughters and the stories they carry - Yahoo News

Posted in Epigenetics | Comments Off on Book review: Daughters and the stories they carry – Yahoo News

TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida…

Posted: September 16, 2022 at 2:23 am

BOCA RATON, Fla., Sept. 14, 2022 /PRNewswire/ -- From breakthroughs in the prevention of post-concussion syndrome to unprecedented advances in post-stroke, traumatic brain injury and spinal cell regeneration, TransMedia Group will bring major media attention to Hyperbaric Oxygen Therapy (HBOT) and one of the fields' greatest pioneers, Veteran Hall of Famer Raymond Cralle.

"With HBOT, patients breathe pure oxygen in a pressurized chamber, helping injured or damaged cells begin to replicate, ultimately creating new, non-injured cells," said TransMedia Group President, Adrienne Mazzone. "Our PR campaign will highlight the outcomes from Cralle's groundbreaking studies of brain and spine injured veterans, and the staggering outcomes. We will educate the media on HBOT's powerful anti-inflammatory effects, including Cralle's protocols which have broken science barriers and are proven to grow new healthy stem cells."

To further build credibility and awareness, TransMedia Group will highlight many of the prestigious recognitions Cralle has received from top neurologists around the world, including the Hyperbaric Medicine Symposium, support from Florida Senator Tom Wright resulting in a Bill through the Florida Legislature and pro-bono care for countless veterans garnering his induction into the Florida Veterans Hall of Fame.

"We believe that HBOT will be more widely practiced as the public learns of its effectiveness," says Raymond Cralle, Founder of Oxygen Rescue Care Centers of America (ORCCA). "That's why TransMedia Group will help simplify the science while also giving reporters and editors our clients' incredible testimonials and home footage- bringing concrete success stories out of the medical journals and into life."

Mazzone says, "'Before' and 'After' Brain Scans are some of the most compelling pitch materials, along with the research that clearly shows how HBOT can sharply decrease veteran suicide rates, diminish the effects of PTSD, including less anger, sleep deprivation and mental anguish."

"We are excited to offer in-depth interviews spotlighting veterans, elite athletes, stroke patients, anti-aging enthusiasts and families who have had their lives changed at Cralle's outpatient neuropathic hyperbaric center in Delray Beach, Florida," said Mazzone. Cralle and his 501 C.3. Hope Springs are at the start of new horizons for HBOT.

TransMedia Group is an international public relations firm serving clients worldwide since 1981. One of its core niches is healthcare and wellness.

Media Contact:Adrienne Mazzone amazzone@transmediagroup.com 561-908-1683

View original content:https://www.prnewswire.com/news-releases/transmedia-group-to-illumine-impressive-neuro-healing-results-achieved-by-raymond-cralle-a-pioneer-in-hyperbaric-oxygen-therapy-and-a-florida-veterans-hall-of-famer-301623749.html

SOURCE TransMedia Group

Read the rest here:
TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida...

Posted in Florida Stem Cells | Comments Off on TransMedia Group to Illumine Impressive Neuro Healing Results Achieved by Raymond Cralle, a Pioneer in Hyperbaric Oxygen Therapy and a Florida…

A history of blood cancer treatment – – pharmaphorum

Posted: September 16, 2022 at 2:16 am

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to other types of the disease. In fact, according to Blood Cancer UK research, more than half of UK adults cannot name a single symptom of blood cancer.

Over the past two centuries, researchers have identified more than 100 different types of blood cancer, while most patients may be familiar with the big three (leukaemia, lymphoma, and melanoma). However, myelodysplastic syndromes and myeloproliferative neoplasms are also prominent types of blood cancer.

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. However, there is still much to be done to achieve a vision wherein all those diagnosed with blood cancer survive.

As we enter Blood Cancer Awareness month, a global event dedicated to spotlighting and supporting efforts to improve awareness, detection, and treatment of blood cancer, we take a look back in celebration of the achievements and breakthroughs that paved the way for todays innovations.

1832 Discovery of Hodgkins and non-Hodgkins lymphoma

Although early accounts of an illness akin to leukaemia can be traced back to Ancient Greece, the first official description of blood cancer didnt appear until 1832, when British pathologist and pioneer of preventative medicine Thomas Hodgkin used the controversial concept of micrology to identify the abnormalities in the lymphatic system.

During his time working in the pathology museum at Guys Hospital in London, Hodgkin studied several preserved specimens of human organs affected by disease. Noticing a pattern in the lymph nodes and spleen that indicated the appearance of disease, he published his findings in a paper entitled, On Some Morbid Appearances of the Absorbent Glands and Spleen.

At the time, his hypothesis appeared to fall on deaf ears, and it would take a further three decades before Hodgkins discovery was recognised.

1844 First reported case of multiple myeloma

The first well-documented case of multiple myeloma was reported in 1844 by renowned British surgeon Samuel Solly. In 39-year-old patient Sarah Newbury, Solly observed the appearance of fatigue and bone pain resulting from multiple fractures. Only four years after the patient first showed symptoms, she died, and an autopsy revealed abnormalities in the bone marrow that closely matched the autopsy findings of 45-year-old Thomas Alexander McBean.

McBeans case is perhaps the most well-known account of multiple myeloma. Similar to Newbury, McBean known to be a highly respected tradesman developed fatigue and severe pain from weak and easily broken bones. After attempts to treat McBeans symptoms through cupping, applying leeches for maintenance therapy, and therapeutic phlebotomy proved unsuccessful, his physician, Dr Thomas Watson, prescribed steel and quinine, while a sample of his urine was sent to chemical pathologist Henry Bence Jones.

Following his death in 1846, histologic examination of McBeans bone marrow revealed a red gelatiniform substance consisting of nucleated cells, some twice the size of an average blood cell.

1847 Virchow links tumours and white blood cells

By the 1840s, histology (the study of microscopic anatomy) was a recognised discipline in the scientific community. Building upon early descriptions of leukaemia by French anatomist and surgeon Alfred-Armand-Louis-Marie Velpeau, in 1847, the father of modern pathology Dr Rudolf Virchow and English physician John Hughes Bennett independently observed abnormal increases in white blood cells in patients.

Virchow was the first to argue that cancer derives from changes in normal cells. Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system.

As with Hodgkins discovery, Virchows theory went almost unnoticed until the 20th century.

1907 The magic bullet of immunotherapy

In the early 1900s, researchers uncovered the existence of several types of blood cancer. However, effective treatments were not available at the time. During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors.

Further research led Ehrlich to develop his side-chain theory, that antibodies produced by white blood cells act as receptors on the cell membrane. For his contribution, in 1908, Ehrlich received the Nobel Prize for Medicine in the field of immunology, together with the father of innate immunity, Ilia Metschnikow, whose discovery of phagocytosis formed the foundation of cell-mediated immunity.

While they may not have known it at the time, through their work Ehrlich and Metschnikow formed the cornerstone of modern immunology, including chemoreceptor and chemotherapy concepts that revolutionised blood cancer treatment over the following century.

1942 Chemotherapy moves from trenches to treatment

In the aftermath of World War I, medical researchers noticed that the mustard gas used to make chemical weapons for the battlefield also destroyed lymphatic tissue. Early experiments showed that topically applying nitrogen mustard caused tumours to shrink in mice.

Research into the medical potential of mustard gas stagnated until 1942, when two assistant professors at Yale, Louis S Goodman and Alfred Gilman, began to study the effects of nitrogen mustard on lymphoma. Although clinical trials proved that chemicals could be used to treat cancer, the results of the study remained a closely guarded military secret until 1946.

1956 The rise of bone marrow transplants

In a milestone achievement for blood cancer research and treatment, Dr E Donnall Thomas performed the first successful bone marrow transplant in 1956. The procedure involved transplanting bone marrow between identical twins, with tissue taken from the healthy twin given to the other who had leukaemia.

In 1968, the first bone marrow transplant using a matched donor took place at the University of Minnesota. Using a blood test developed by Dr Fritz Bach, Dr Robert Good determined that the patient, a baby with a severe immune deficiency, was a human leukocyte antigen match with his nine-year-old sister.

The ground-breaking approach to donor selection paved the way for future bone marrow transplants, including the first successful bone marrow transplant with unrelated patients in 1973.

Before the birth of bone marrow transplants, patients were often treated using chemotherapy, which could be used to kill cancer cells. However, this also presented a problem: chemotherapy does not discriminate between healthy and cancer cells, meaning that if patients were given sufficient doses to kill the disease, normal cells would also be harmed. With the advent of bone marrow transplantation, these healthy cells could be replaced with donor cells, allowing for higher doses of chemotherapy in treatment.

1980s Emergence of cord blood transplants

Another source of haematological stem cells emerged in the late 80s cord blood stem cells. The remaining blood found within the umbilical cord and placenta after birth is rich in blood-producing stem cells. Cord blood collection has rarely changed since the first successful procedure occurred in 1988.

Stem cells extracted from a donated cord can be frozen for a number of years and quickly accessed when needed. Once the transplant is complete, the cells will travel into the patients bone marrow, where they will begin to grow into normal blood cells.

Recognising the need to identify and match potential donors with patients, in 1989 the Bone Marrow Donors Worldwide programme was established.

Today, the bone marrow donor registry comprises more than 39,527,166 donors and 804,246 cord blood units.

2001 FDA green lights revolutionary treatments

Innovation in blood cancer treatments ushered in a new generation of targeted and precision treatments. One such therapy was Imatinib (also known as Gleevec or Glivec), a first-generation tyrosine kinase inhibitor dubbed a magical bullet, designed to specifically target BCR-ABL tyrosine kinase.

Just over a decade after it was developed by biochemist Nicholas Lyndon, Imatinib received US Food and Drug Administration (FDA) approval in 2001. Since then, it has transformed the treatment of chronic myeloid leukaemia and non-Hodgkins lymphoma.

The following year, the regulator also approved Rituximab, a monoclonal antibody targeting CD-20 positive B-cells, as a companion treatment of chemotherapy in older diffuse large B-cell lymphoma patients.

2002Emergence of CAR-T therapy

Building on the success of cytokine-based immunotherapies, scientists continued to seek other areas where the immune system could be leveraged against tumours. Throughout the 90s, Dr James Allison spearheaded research into T-cell engineering, a revolutionary technique that formed the foundation of chimeric antigen receptor (CAR) T-cell therapy.

Dr Allisons research into the function and application of T-cells in cancer treatment greatly broadened scientific understanding of the immune system. However, the first generation of CAR T-cells proved to be clinically ineffective.

It wasnt until 2002, when Memorial Sloane Kettering Cancer Center scientists Michel Sadelain, Renier Brentjens, and Isabelle Rivire opted to push the boundaries of research, by genetically engineering T-cells with a CAR, that the technique achieved successful results.

This research paved the way for the first successful treatment of a patient with acute lymphoblastic leukaemia in 2011.

2012 The 100,000 Genomics Project begins

Unlocking the secrets of the human genome has intrigued investigators for centuries. However, the technology needed to analyse genomic and long-term clinical data is a relatively recent development. With the launch of the 100,000 Genomes Project in 2012, an international team of researchers studied the role that genes play in health and disease.

For the first time, researchers demonstrated that whole genome sequencing could be used to uncover new diagnoses across the broadest range of rare diseases. This was an entirely new approach to DNA research. Previously, DNA would be segmented into short sections, which would then be read and sequenced separately.

The 100,000 Genomes Project sparked a new wave of research exploring the clinical potential of sequencing long strands of individual DNA without cutting them into sections. With this technique, it is hoped that researchers will gain previously inaccessible insights into cancer, revealing more accurate diagnoses and treatment pathways for patients.

20162022 New treatments enter the market

Over the past few years, the number of treatments approved for blood cancer has skyrocketed. Johnson & Johnsons Darzalex (daratumumab) was a notable development for the sector. The monoclonal antibody first received FDA approval in November 2015 as a monotherapy for patients with multiple myeloma, marking it as the first CD38-directed antibody to receive regulatory approval to treat the disease. It has since gone on to receive numerous approvals for multiple myeloma designations.

As of 2022, more than 800 new cell therapies are being developed for five blood cancers, with the market for oncology cell therapies expected to exceed $37 billion in value globally by 2028.

If you liked this story, check out the related video below.

Continue reading here:
A history of blood cancer treatment - - pharmaphorum

Posted in Minnesota Stem Cells | Comments Off on A history of blood cancer treatment – – pharmaphorum

Diversifying marrow registry critical to achieve medical equity say advocates – WISH TV Indianapolis, IN

Posted: September 16, 2022 at 2:15 am

INDIANAPOLIS (WISH) The Be the Match marrow registry has more than 39 million people signed up and willing to donate bone marrow or stem cells to those with blood cancers or other diseases, but the chances of find a match drop significantly for non-white patients.

Tarita Gibson with Be the Match said, The gap is for African-Americans 29% youll find a donor on the registry to 79% of Caucasian will find a donor on the registry.

For Asian or Pacific Islander patients, there is a 47% chance of finding a match. Hispanic patients have a 48% chance of finding a match while there is a 60% chance for Native-Americans. Gibson said because donors and patients need to share a similar genetic background to match, they need more diversity on the list to save lives.

Gibson said, We want to have equal outcomes for all ethnic backgrounds, so its very important for people between the ages of 18-40 to join the registry, [and] get some education about the registry.

One local doctor said donating bone marrow requires a minor surgical procedure and stem cell donation is similar to donating blood.

Dr. Yogesh Jethava, a Medical Oncologist at Indiana Blood and Marrow Transplantation, said, The blood comes out of here, goes into the machine, the machine takes the stem cells, we call them mononuclear cells, they are taken out, and the rest of the blood is pushed back in you.

Joining the registry is even easier. All you have to do is request a kit to your house, swab your mouth and send it back, then you are placed on a list and could be matched with anyone in the United States. This is important because family members are often not a match.

Jethava explained, DNA is made up of four different strands and there is no garuntee that me and my brother will inherit exactly the same half from the parents.

Be the Match is working to expand the registry with continued outreach and education.

We do a lot of awareness events where people come to get awareness and learn what its all about, Gibson said. We educate groups all the time, student groups, organizations, corporations, we really need more donors on the registry.

You can join the bone marrow registry be signing up here.

Continue reading here:
Diversifying marrow registry critical to achieve medical equity say advocates - WISH TV Indianapolis, IN

Posted in Indiana Stem Cells | Comments Off on Diversifying marrow registry critical to achieve medical equity say advocates – WISH TV Indianapolis, IN

Exercise is Preventative Medicine – myBurbank.com

Posted: September 16, 2022 at 2:14 am

Before I dive in, let me be clear. Exercise should not be used in place of prescribed medications that you need to manage chronic conditions, such as diabetes, cholesterol, hypertension, irregular heartbeats or anything of the nature. What the science clearly shows though, is that exercise is an effective preventative medicine that can prevent the onset of many of the leading illnesses in the U.S. In fact, the CDC lists lack of physical exercise as one of the four primary risk factors for chronic disease. Incidentally, the others are tobacco use, poor nutrition, and excessive alcoholic consumption.

So, what conditions may be avoidable, or less likely to develop if you engage in regular exercise that includes any combination of cardio, strength training and deep stretching?? The list is long:

Exercise: Specific Ways it Improves Your Health

Exercise is considered pleiotropic, meaning that it has multiple beneficial effects on the body. It positively impacts brain function because it leads to better sleep. It also supports a healthy blood-brain barrier which is the group of blood vessels responsible for keeping pathogens and toxins out of the brain, and letting healthy cells and molecules reach the brain. Regular exercise also helps protect the neurons in the brain from inflammation and damage. Neuron damage has been correlated with Parkinsons Disease, Alzheimers Disease, and Multiple Sclerosis.

Exercise benefits your musculoskeletal system in many ways as well. It strengthens muscles and bones putting you at less risk for low bone density (osteoporosis). It also keeps joints mobile and healthy, reducing the risk of arthritis. This therefore reduces your risk of falling as you age. For those who already have arthritis, exercise can reduce pain and inflammation.

There may be no treatment more underused than exercise when it comes to treating stress, anxiety, and depression. Exercise reduces levels of adrenaline and cortisol in the body. These are the hormones that cause stress and anxiety. At the same time, working out helps to increase your production of endorphins, which are your brains feel good neurotransmitters. As mentioned, exercise is pleiotropic, so this reduction in stress then aids in healthy digestion, better, sleep, and overall better mental health.

Youll do your cardiovascular system a favor by working out regularly as well. Regular fitness routines help improve blood flow in your heart. By increasing the flow of oxygen-rich blood throughout your body, you can prevent the buildup of plaque in your arteries, which is a leading cause of heart disease.

Your respiratory system also benefits from a regular exercise routine. This is because when youre walking, running, jogging, cycling, or lifting weights your lungs and heart are forced to work harder. After all, they must supply the oxygen that your muscles need. So, exercising is not only working your muscles, but also giving your lungs a workout, too.

Regular exercise also helps prevent obesity. Obesity is an epidemic in this country. There is nothing wrong with body positivity. However, being significantly overweight is not healthy. It causes stress on your heart, on your organs, on your joints, muscles, and bones. Obesity rarely occurs in a vacuum. It is almost always found in conjunction with other chronic illnesses or conditions including high blood pressure, heart disease, diabetes, high cholesterol, and more. No one should be ashamed of their body. But the science is clear that carrying extreme amounts of excess weight puts your health, and even your life at risk.

Get Help Starting an Exercise Routine

If youve been a bit of a couch potato, since the pandemic hit, dont beat yourself up. It happened to the best of us. But it is time to get back on track and prioritize health. Reach out to an active friend or family member. Schedule a consultation with a personal trainer, or use a streaming video at home to ease yourself back in. It doesnt matter how you start, its just important that you do start. But dont just take it from me. Even doctors will tell you that prevention is the best medicine. And thats exactly what exercise is: preventative medicine.

About SY Performance

SY Performance offers in-person and hybrid training at Conquer All Things Fitness Studio, located at 1218 Magnolia Blvd in Burbank. SY Performance was founded by Burbank-based celebrity personal trainer Scott Yonehiro. Yonehiro created and launched the first 90 Day Body Transformation Program in 2010. To date, thousands of individuals have completed the program, which utilizes a proprietary combination of science-based techniques coupled with fitness, nutrition, and mindset exercises to help individuals of all ages lose weight, reduce body fat, and increase muscle.

Visit: http://www.syperformanceone.com

Email: Scott@syperformanceone.com

YouTube: https://www.youtube.com/c/ScottYonehiro1

Facebook: https://www.facebook.com/syperformanceone

Instagram: https://www.instagram.com/syperformance/

Twitter: https://twitter.com/SYPerformance

Read more:
Exercise is Preventative Medicine - myBurbank.com

Posted in Preventative Medicine | Comments Off on Exercise is Preventative Medicine – myBurbank.com

Best preventative medicine, health screening and anti-ageing clinics for HNWs in 2022 – Spear’s WMS

Posted: September 16, 2022 at 2:14 am

Welcome to the Spears ranking of the preventative medicine specialists for high-net-worth individuals in the UK. The list features our Top Recommended companies

Health monitoring and early scanning can help catch potentially serious problems in their early stages, especially some cancers and heart problems. A day a year spent in the comfortable surroundings of one of the clinics on the Spears preventative medicine index will pay dividends any HNW would be happy with.

Let Richard Pisarskis staff at the seven-story Mayo Clinic on Portland Place in London guide you through a series of tests and scans, for example, or attend one of Paul Jenkins pioneering European Scanning Centres.

Spears publishes annual rankings of the top private client advisers, service providers and companies that cater to HNWs. These are drawn up on the basis of peer nominations, client feedback, telephone and face-to-face interviews, data supplied by firms, as well as information gathered by the Spears editorial and research teams.

Click on the individual names to be directed to more detailed profiles on spears500.com. The table is ordered alphabetically by name.

To explore all the Spears indices, and to use our find-an-adviser tool to identify the private client adviser who is right for your specific requirements, go to theSpears 500 website.

To receive relevant research updates from Spears and thereby give you and your firm the best chance of being included in future Spears indices pleaseregister here.

If you are an adviser featured in index and would like to update your profile or provide additional information, please email rasika.sittamparam@spearswms.com.

See the rest here:
Best preventative medicine, health screening and anti-ageing clinics for HNWs in 2022 - Spear's WMS

Posted in Preventative Medicine | Comments Off on Best preventative medicine, health screening and anti-ageing clinics for HNWs in 2022 – Spear’s WMS

The high hospital bills we make victims of rape and sexual violence pay – Vox.com

Posted: September 16, 2022 at 2:13 am

When victims of rape or sexual violence seek emergency medical assistance following an attack, they may be saddled with hundreds or even thousands of dollars in medical bills, a new study published this week in the New England Journal of Medicine found.

These bills can further traumatize victims, the study authors warn, and deter others from seeking professional help. Only one-fifth of sexual violence victims are estimated to seek medical care following an attack.

Researchers affiliated with Harvard analyzed a nationwide data set of more than 35 million emergency room visits in 2019, the most recent year such information was available. They looked specifically at visits where doctors billed with codes related to care after sexual assault, and found more than 112,000 such patients. Nearly 90 percent of those patients were female, and 38 percent were children under 18.

When victims of sexual violence go to the ER, there are two kinds of care theyd typically receive. The first is a sexual assault forensic exam, or more colloquially, a rape kit. Thats where a medical professional collects evidence from a victim, such as conducting a pelvic, rectal, or throat exam, taking samples for a DNA test, and looking for semen or any other evidence of violent injury.

Under the Violence Against Women Act (VAWA) of 1994, the costs associated with a forensic exam are paid for with public funds, and while survivors are sometimes erroneously billed, the federal law prohibits charging victims for the cost of their evidence collection.

But VAWA does not cover the second category of care and thats therapeutic care, or whatever is medically necessary for a persons health following an attack.

So for instance, doctors frequently give victims preventative medication for STDs, like antibiotics to prevent syphilis, gonorrhea, or HIV medication if thats a possibility, said Stephanie Woolhandler, one of the lead authors of the study. ER physicians may also provide emergency contraception to victims if pregnancy is a concern, and in other cases victims may have vaginal or rectal lacerations that need to be sewn up, other injuries, or broken bones.

The researchers findings on the costs of such care are sobering. Uninsured victims, who numbered over 17,000 in 2019, faced out-of-pocket charges averaging $3,673.

For all the roughly 112,800 patients seen for sexual assault who visited the ER that year, charges averaged $3,551, with even higher averages for pregnant patients ($4,553). Insured patients had lower out-of-pocket bills, but how much lower depends on the structure of their insurance plan. Prior research suggests that even those with private insurance paid about 14 percent of their bill on average, roughly $500. That can be an enormous sum of money given that a disproportionate share of sexual assault victims are low-income women and girls, Woolhandler told Vox.

The findings, published less than three months following the Supreme Courts overturn of Roe v. Wade, come as states move to restrict not only access to abortion but other basic sexual health care treatments, like emergency contraception and drugs used to manage miscarriages.

Samuel Dickman, an abortion provider and lead study author, told Vox that when he used to provide care in Texas (he relocated to Montana in May), he personally encountered patients who came in following sexual attacks who were then vulnerable to catastrophic medical bills. Texas has the highest uninsured rate in the country, and this research is a start towards quantifying that vulnerability, he said.

The vulnerability isnt limited to the uninsured, though. Dickman recalls one of his former patients who had been raped and became pregnant, and was seeking an abortion. She was on Medicaid, and under the Hyde Amendment, rape victims should have had that procedure covered but Texas has made it so hard that we were looking at charging this victim more than $1,000 out of pocket, he said. Those charges were just shocking to her, and on top of having just been raped, frankly, it was haunting.

The study authors are urging policies that ensure affordable access to all essential medical services including abortion and emergency contraception for survivors of rape, and for everyone else who needs that care, said Dickman.

One option they suggest in their paper to help survivors of sexual violence would be to expand VAWA to cover therapeutic services, not just evidence collection. Woolhandler told Vox that that would be a step in the right direction but that ultimately more comprehensive reform, including universal health care coverage, is needed to eliminate barriers.

Sexual health care is health care and we, like other developed nations, ought to be making all health care free at the time of use, Woolhandler added. In a post-Roe world, an unwanted pregnancy can mean an unwanted childbirth, and so the government has the power to force you as someone with a vagina to bear all the consequences of your attack, not just a $500 or $3,000 medical charge, but you have to also bear this child. Its frankly outrageous.

Paying greater attention to privacy concerns of survivors, the study authors urge, is also paramount to ensuring victims feel they can seek the care they need. Emergency department charges may discourage the reporting of rape and seeking of medical care for both short-term and long-term sequelae of sexual assault, the NEJM study states. Incurring such charges may further harm survivors even those with full insurance coverage by serving to disclose a potentially stigmatizing event to parents, partners, or employers.

Dickman said theres no reason we couldnt have a system where every individual has their own insurance card that entitles them to private care. Ive seen insured patients say theyll pay for their care out of pocket even if that means theyll have to skip rent or groceries, because they cant have that kind of disclosure to their family or employer about abortion or sexual assault, he said. If youre a minor seeking emergency room care, theres a good chance the primary insurance policy holder will be getting a list of what services you received, and very plausibly, that person could be the person who committed the assault.

Woolhandler said some of the privacy concerns stem from private insurance, because insurers are entitled to know what procedures were done and diagnoses made. Part of the thing with single-payer is hospitals dont send bills, she said. In Canada, hospitals get a lump sum that they use to pay all their operations; presumably, theres a record at the hospital about who you are and your [medical] record, but it doesnt have to leave the hospital.

We need to not tie people to their jobs or their family members in terms of medical care, added Dickman. Its just a crazy way to structure a system.

Excerpt from:
The high hospital bills we make victims of rape and sexual violence pay - Vox.com

Posted in Preventative Medicine | Comments Off on The high hospital bills we make victims of rape and sexual violence pay – Vox.com

Press Release: CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants – StreetInsider.com

Posted: September 16, 2022 at 2:13 am

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants

Paris, September 16, 2022. The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. If approved, Beyfortus would be the first and only single-dose passive immunization for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions. Beyfortus is being developed jointly by Sanofi and AstraZeneca.

Jean-Franois ToussaintGlobal Head of Research and Development Vaccines, Sanofi Todays positive CHMP opinion is one of the most significant public health achievements in RSV in decades and has the potential to alleviate the enormous physical and emotional burden that RSV can place on families and healthcare systems. With this endorsement, we are one step closer to achieving our goal of protecting all infants against RSV with a single dose.

Iskra ReicExecutive Vice President, Vaccines and Immune Therapies, AstraZenecaThis positive CHMP opinion underscores Beyfortus potential as a ground-breaking, first-in-class passive immunization that could transform the medical communitys approach to RSV prevention in infants.

The CHMP based its positive opinion on results from the Beyfortus clinical development program, including the Phase 3 MELODY, Phase 2/3 MEDLEY, and Phase 2b trials.1-8 In the MELODY and Phase 2b trials, Beyfortus met its primary endpoint of reducing the incidence of medically attended lower respiratory tract infections (LRTI) caused by RSV during the RSV season vs. placebo with a single dose. 1-6 The safety profile of Beyfortus was similar to placebo. Beyfortus also demonstrated a comparable safety and tolerability profile to palivizumab in the Phase 2/3 MEDLEY trial.7-8

RSV is the most common cause of LRTIs and a leading cause of hospitalization in all infants, with most hospitalizations occurring in infants born healthy and at term.9-13 RSV-related direct medical costs, globally including hospital, outpatient and follow-up care were estimated at 4.82 billion in 2017.14 Currently there is no preventative option available for all infants and treatment is limited to symptomatic relief.15,16

About Beyfortus

Beyfortus (nirsevimab), an investigational long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly by Sanofi and AstraZeneca.

Beyfortus has been developed to offer newborns and infants direct RSV protection via an antibody to help prevent LRTI caused by RSV. Monoclonal antibodies do not require the activation of the immune system to help offer timely, rapid and direct protection against disease.17

In March 2017, Sanofi and AstraZeneca announced anagreementto develop and commercialize Beyfortus. Under the terms of the agreement, AstraZeneca leads all development and manufacturing activities and Sanofi will lead commercialization activities and record revenues. Under the terms of the global agreement, Sanofi made an upfront payment of 120m, has paid a development milestone of 30m and will pay up to a further 465m upon achievement of certain development and sales-related milestones. The two companies share all costs and profits. Revenue from the agreement is reported as Collaboration Revenue in the Companys financial statements.

Beyfortus has been granted designations to facilitate expedited development by several major regulatory agencies around the world. These include Breakthrough Therapy Designation by The China Center for Drug Evaluation under the National Medical Products Administration;Breakthrough Therapy Designationfrom the US Food and Drug Administration; access granted to the European Medicines Agency (EMA)PRIority MEdicinesscheme; Promising Innovative Medicine designation by the UK Medicines and Healthcare products Regulatory Agency; and named a medicine for prioritized development under the Project for Drug Selection to Promote New Drug Development in Pediatrics by the Japan Agency for Medical Research and Development (AMED). The safety and efficacy of Beyfortus was evaluated under an accelerated assessment procedure by the EMA. Beyfortus has not been approved by any regulatory authority.

About the clinical trials

The Phase 2b trial was a randomized, placebo-controlled trial designed to measure the efficacy of Beyfortus (nirsevimab) against medically attended LRTI through 150 days post-dose. Healthy preterm infants of 2935 weeks gestation were randomized (2:1) to receive a single 50mg intramuscular injection of Beyfortus or placebo. The primary endpoint was met, reducing the incidence of medically attended LRTI, caused by RSV by 70.1% (95% CI: 52.3, 81.2) compared to placebo. Between November 2016 and December 2017, 1,453 infants were randomized (Beyfortus, n=969; placebo, n=484) at the RSV season start. Studies were conducted in both hemispheres, at 164 sites in 23 countries.3,4Data was publishedin theNew England Journal of Medicine(NEJM)in July 2020. The dosing regimen was recommended based on further exploration of the phase 2b data.3 The subsequent Phase 3 study, MELODY, applied the recommended dosing regimen.2

The Phase 3 MELODY trial was a randomized, placebo-controlled trial conducted across 21 countries designed to determine efficacy of Beyfortus against medically attended LRTI due to RSV confirmed by reverse transcriptase polymerase chain reaction testing through 150 days after dosing, versus placebo, in healthy late preterm and term infants (35 weeks gestational age or greater) entering their first RSV season.1,2The primary endpoint was met, reducing the incidence of medically attended LRTI, such as bronchiolitis or pneumonia, caused by RSV by 74.5% (95% CI 49.6, 87.1; PNEJMin March 2022.

Findings from Beyfortus clinical trial program include a pre-specified pooled analysis of the Phase 3 MELODY trial and the recommended dose from the Phase 2b trial, in which an efficacy (relative risk reduction versus placebo) of 79.5% (95% CI 65.9, 87.7; PNEJMin March 2022.1,5

MEDLEY was a Phase 2/3, randomized, double-blind, palivizumab-controlled trial with the primary objective of assessing safety and tolerability for Beyfortus in preterm infants and infants with congenital heart disease (CHD) and/or chronic lung disease of prematurity (CLD) eligible to receive palivizumab.7,8 Between July 2019 and May 2021, approximately 918 infants entering their first RSV season were randomized to receive a single 50mg (in infants weighing NEJM in March 2022.

The results of MELODY, Phase 2/3 MEDLEY and the Phase 2b trials illustrate that Beyfortus helps protect infants during their first RSV season against RSV disease with a single dose.1-8 This all-infant population includes preterm, healthy late preterm and term infants, as well as infants with specific conditions.

These trials form the basis of regulatory submissions that began in 2022.

About RSV

RSV is the most common cause of LRTI, including bronchiolitis and pneumonia, in infants.9It is also a leading cause of hospitalization in all infants, with most hospitalizations for RSV occurring in healthy infants born at term.10-13 Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalizations, and it was estimated that there were 26,300 in-hospital deaths of children younger than five years.18 RSV-related direct medical costs, globally including hospital, outpatient and follow-up care were estimated at 4.82 billion in 2017.14

About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve peoples lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media RelationsSandrine Guendoul|+ 33 6 25 09 14 25 |[emailprotected]Sally Bain|+ 1 617 834 6026 |[emailprotected]Nicolas Obrist|+ 33 6 77 21 27 55 |[emailprotected]Kate Conway|+ 1508364 4931 |[emailprotected]

Investor RelationsEva Schaefer-Jansen|+ 33 7 86 80 56 39 |[emailprotected]Arnaud Delpine|+ 33 6 73 69 36 93 | [emailprotected]Corentine Driancourt|+ 33 6 40 56 92 21 | [emailprotected]Felix Lauscher|+ 1908612 7239 | [emailprotected]Priya Nanduri | + 1 617 764 641 |[emailprotected] Nathalie Pham|+ 33 7 85 93 30 17 | [emailprotected]

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although Sanofis management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofis ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofis annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

References

Excerpt from:
Press Release: CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants - StreetInsider.com

Posted in Preventative Medicine | Comments Off on Press Release: CHMP recommends approval of Beyfortus (nirsevimab) for prevention of RSV disease in infants – StreetInsider.com

Why Now is the Time to Double Down on Virtual Care – HIT Consultant

Posted: September 16, 2022 at 2:13 am

Dr. Ron Moody, Chief Medical Officer, Accenture Federal Services

For an industry that traditionally embraces change at a glacial pace, the pandemic has been a wake-up call for healthcare. Once COVID-19 struck, the shift to video, telephone engagement and remote patient monitoring spiked seemingly overnight.

This surging demand for virtual care resulted, in many cases, in increased provider efficiency, provider-patient interactions, and satisfaction. One national telehealth organization covering 2,000 hospitals and 81,000 doctors, for example, experienced an 86% decrease in time needed to complete the patient onboarding process, and 92% of providers said they expect to continue video visits post-pandemic. Access also improved a Johns Hopkins University study found that Medicare beneficiaries in poor neighborhoods increased their use of telemedicine during the pandemic.

In short, weve learned that virtual care is scalable, trusted, adaptable, and even preferable for many patients and clinicians alike.

No time to rest

But this isnt the time for the industry to go back to the old way of doing business. Healthcare organizations should leverage lessons learned from the pandemic to create fundamental change. That means shifting away from reactive medicine to proactive and preventative care, wellness, population health, and better support for chronic conditions.

We need to think differently because, frankly, incremental change around the same ideas hasnt worked. A recent studyby the Commonwealth Fund found that, despite spending far more of its gross domestic product on health care than 10 other high-income nations, the U.S. ranked last in access to care, administrative efficiency, equity, and healthcare outcomes.

Transforming the healthcare system wont be easy. Structural hurdles such as regulatory constraints and legacy payment models, as well as simple inertia, have conspired to block the path forward. Too often, providers are incentivized to provide direct, in-office care instead of using the best mode available to address a patients specific needs.

Federal agencies: catalysts of change

Federal healthcare providers, such as the Veterans Health Administration (VHA), Defense Health Agency, and Indian Health Service are uniquely positioned to lead this transformation. These agencies serve a large portion of the U.S. population and are dedicated to patient-centered, evidence-based care. Importantly, their financial models are different from those of commercial healthcare providers, enabling them to disrupt the status quo.

Because these federal agencies operate largely as integrated healthcare systems, they can more readily implement policy and procedural changes as well as the enabling technology which can minimize and manage potential disruption, while achieving improved outcomes.

Furthermore, they can more quickly capture cost savings and other efficiencies for reinvestment to expand adoption and improve care quality and convenience. Most agencies have already been making significant investments in virtual care.

VHA leads the way

Consider the VHA, for example. It is the largest integrated health care system in the U.S., providing care at nearly 1,300 health care facilities and more than 1,100 outpatient clinics, serving 9 million enrolled veterans each year. VHAs Connected Care program has been a pioneer and innovator in using video visits at scale, conducting more than 750,000 virtual visits per month in 2021.

Because they have laid the groundwork for virtual care, the VHA and other federal agencies will be able to accomplish more by tying those investments to a broader model we call Virtual First a strategic framework for transforming patient experiences and outcomes using data-driven innovation.

Reimagined approach

A Virtual First approach uses remote, digital engagement as the default care delivery method whenever appropriate to improve patient and provider experiences, reduce costs and improve outcomes.

It does not, of course, replace todays in-person ambulatory and critical care services. Rather, it complements, enhances, and where appropriate, replaces traditional in-person care. A Virtual First strategy matches the means of care delivery to the case, factoring in the specific patient, his or her condition, the urgency, and the needed staff.

Virtual First provides new opportunities for clinicians to consult with patients regularly and outside of traditional care settings. It allows for more effective monitoring and interventions. A providers ability to impact patient health is no longer bound by the limited time spent interacting with patients in medical offices, nor is it constrained by a lack of data.

Private sector innovation

Besides the federal healthcare providers cited above, private sector health organizations have also pioneered patient-centric models driven by technology.

A recent Harvard Business Review article The Telehealth Era Is Just Beginning, describes how two of the earliest telehealth adopters Kaiser Permanente and Intermountain Healthcare leverage sophisticated technology to improve access to care, deliver care more efficiently, and reduce unnecessary emergency room visits.

Kaiser members in some states can access a round-the-clock video health center connecting them with telehealth doctors who resolve the issue 60% of the time, thereby avoiding a costly trip to the ER. The doctor can also schedule an appointment with the members personal physician if follow-up care is needed and provide details of the patients issue before the appointment.

Similarly, using remote home monitoring technology and a telemedicine program during the pandemic, Intermountain avoided more than 1,800 hospital admissions and saved almost 4,800 hospital bed-days, which freed up beds for the sickest patients.

A word of caution

Virtual care has demonstrated its ability to serve as a catalyst and enabler for much-needed improvements of the healthcare system.

However, simply using it as an alternate way to deliver the same type of care wont change outcomes drastically. It will not address the growing doctor and nursing shortage. It may provide another avenue of convenient health access, but it will be yet another innovation that falls short of its promise unless it is accompanied by a true outcomes-based, patient-centric strategy, enabled by technology and data.

About Dr. Ron Moody

Dr. Ron Moody is currently the Chief Medical Officer at Accenture Federal Services. He is a retired Army Colonel who served in the military for more than two decades. Dr. Moody is board-certified in family medicine with a broad background in medicine, clinical operations, Healthcare administration, strategic planning, and health information technology.

See the original post:
Why Now is the Time to Double Down on Virtual Care - HIT Consultant

Posted in Preventative Medicine | Comments Off on Why Now is the Time to Double Down on Virtual Care – HIT Consultant

Page 238«..1020..237238239240..250260..»